共 50 条
- [41] Hyper-CVAD Plus Ponatinib as Frontline Therapy in Philadelphia Chromosome-Positive (Ph plus ) Acute Lymphoblastic Leukemia (ALL): Updated Results of a Phase II Trial CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 : S257 - S258
- [43] Ponatinib Versus Imatinib with Reduced-Intensity Chemotherapy in Patients with Newly Diagnosed Philadelphia Chromosome-Positive (Ph plus ) Acute Lymphoblastic Leukemia (ALL): PhALLCON Study CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S269 - S269
- [45] Clinical Correlation between Translocation Variant and Outcome in Philadelphia Chromosome-Positive Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia Patients JOURNAL OF MOLECULAR DIAGNOSTICS, 2018, 20 (03): : S31 - S31
- [46] Genetic correlates in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with Hyper-CVAD plus dasatinib or ponatinib Leukemia, 2022, 36 : 1253 - 1260
- [48] Discovery of a Selective PROTAC Degrading Untamable BCR::ABL1 Compound Mutants in Chronic Myelogenous Leukemia (CML)and Philadelphia Chromosome-Positive (Ph plus ) Acute Lymphoblastic Leukemia (ALL) CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S336 - S336
- [50] Efficacy and safety of ponatinib for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: a case series from a single institute International Journal of Hematology, 2021, 114 : 199 - 204